Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
Matthew D. Hellmann(AstraZeneca (United States)), Maximilian Diehn(Stanford University), Hira Rizvi(Memorial Sloan Kettering Cancer Center), Ash A. Alizadeh(California Institute for Regenerative Medicine), Mark Dunphy(Memorial Sloan Kettering Cancer Center), Barzin Y. Nabet(Gene Therapy Laboratory), Everett J. Moding(Stanford Medicine), Joel W. Neal(Stanford Medicine), Heather A. Wakelee(Palo Alto Institute), Rene F. Bonilla(Stanford University), Andrew J. Plodkowski(Memorial Sloan Kettering Cancer Center), Mark G. Kris(Memorial Sloan Kettering Cancer Center), Jia Luo(Dana-Farber Cancer Institute), Bob T. Li(Memorial Sloan Kettering Cancer Center), Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Christopher H. Yoo(Stanford University), Chih Long Liu(Stanford University), Henning Stehr(Stanford University), Ryan B. Ko(Stanford University), Sukhmani K. Padda(Stanford University), Mohsen Abu-Akeel(Swim Across America), Angela B. Hui(Stanford University), Isabel R. Preeshagul(Memorial Sloan Kettering Cancer Center), Daniel K. Wells(Parker Institute for Cancer Immunotherapy), Jennifer L. Sauter(Memorial Sloan Kettering Cancer Center), Linda Gojenola(Stanford University), Megan Tenet(Memorial Sloan Kettering Cancer Center), Aadel A. Chaudhuri(Washington University in St. Louis), Jacob J. Chabon(Foresight Science & Technology (United States)), Diego Almanza(Stanford University), Jamie E. Chaft(Memorial Sloan Kettering Cancer Center), Hyejin Choi(Cornell University), Rocio Perez Johnston(Memorial Sloan Kettering Cancer Center), Taha Merghoub(Cornell University)
Cited by 123
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k